IL22 and hepatocellular carcinoma: To explore the mechanism underlying IL-22-enhanced sorafenib resistance, we treated MHCC-97H and HCC-LM3 cell lines with IL-22 at concentrations of 5 ng/ml and 10 ng/ml.